Insilico Medicine Projects First-Half 2026 Profit as AI-Driven Drug Program Reaches Phase III
Insilico Medicine (HKEX: 3696) has issued a profit alert for the first half of 2026, forecasting net income of $33.5 mil...
Read story →
Insilico Medicine (HKEX: 3696) has issued a profit alert for the first half of 2026, forecasting net income of $33.5 mil...
Read story →
On May 14, 2026, the city of Austin became the backdrop for a high‑stakes experiment in rapid‑prototyping AI. The 75...
Read story →
AI workloads are accelerating the construction of new data centers worldwide. Morgan Stanley Research estimates that glo...
Read story →
Arm Holdings plc (NASDAQ: ARM) announced record financial results for fiscal year 2026 and unveiled its first in‑house...
Read story →
On June 23 2026, Cosmos Health Inc. (NASDAQ:COSM) announced a new partnership to install an artificial‑intelligence‑...
Read story →
At the BIO 2026 International Convention in Cambridge, Mass., Insilico Medicine and SK Biopharmaceuticals unveiled a res...
Read story →
Cosmos Health Inc. (NASDAQ:COSM) announced on June 18 2026 that its wholly‑owned subsidiary, CosmoFarm S.A., generated...
Read story →
On June 7, 2026, Birmingham’s TitanUp 26 conference became the stage for a bold pivot: Titan, the UK’s leading pharm...
Read story →
IDBS, a cloud‑software provider for the biopharmaceutical sector, and Alchemi, an applied‑AI company, announced a pa...
Read story →
On June 8‑11, 2026, the 361st Theater Public Affairs Support Element (TPASE) of the U.S. Army Reserve rolled out a hyb...
Read story →
On 12 June 2026, Novo Nordisk A/S announced that attackers had accessed and exfiltrated a limited set of its internal da...
Read story →
When the bell rang on June 12, 2026, the AI‑chip trio—Intel, AMD, and Arm—took the market by storm, sending shares...
Read story →
Arm Holdings plc, the British semiconductor and software design company based in Cambridge, announced on March 24 2026 t...
Read story →